Jessica Merrill
Writes for:
Latest From Jessica Merrill
Tecfidera Headwinds Could Mean Cuts At Biogen, Unless Aducanumab Succeeds
Biogen lowered revenue guidance for the year by $600m due to Tecfidera generics and said it could consider broader cost cuts in 2021 depending on the outcome of aducanumab at the US FDA.
Regeneron's Inmazeb Approval For Ebola Paves The Way In COVID-19
The US FDA approved the first antibody cocktail for ebolavirus infection, supporting a supply contract with BARDA. The development experience informed Regeneron's work in COVID-19.
Revance Builds Therapeutics Credibility For DaxibotulinumtoxinA Ahead Of Aesthetics Launch
The long-acting neuromodulator improved symptoms of cervical dystonia in a Phase III trial with longer duration of efficacy versus older products; a launch for aesthetics is expected soon.
J&J Says It's Wait And See On COVID-19 Vaccine Delay, Outlines Rosier Outlook for 2021
It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.
Mallinckrodt Finalizes Bankruptcy Filing And Opioid, Acthar Settlements
The company will pay $1.6bn to settle opioid litigation and $260m to settle a Medicaid rebate dispute related to Acthar Gel under a restructuring support agreement.
Jazz Phase III Success With Xywav In Idiopathic Hypersomnia Strengthens A Valuable Franchise
The company plans to file for approval in the expanded indication, for which there are currently no approved therapies.